Physician profile
Daniel Bryan Rust
NPI 1841844172
$1,961.82
in general payments reported to CMS, 2019-2025
11 companies · $747 in 2025
The $747 reported for 2025 was more than what 98% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $284 · 2023: $302 · 2024: $629 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,678.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $953.27 | 2022-2025 | Entyvio, Eohilia |
| Abbvie INC. | $447.69 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $196.76 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $89.25 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $86.66 | 2024-2025 | Zenpep |
| Globus Medical, INC. | $66.04 | 2025 | Vyrsa V1, Senza |
| Intercept Pharmaceuticals, INC. | $44.92 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.51 | 2023 | Cyltezo |
| Celgene Corporation | $21.31 | 2022 | |
| Qol Medical, LLC | $18.48 | 2025 | Sucraid |
| Pfizer INC. | $15.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.